{"id":"five-days-oseltamivir","safety":{"commonSideEffects":[{"rate":"10","effect":"Nausea"},{"rate":"8","effect":"Vomiting"},{"rate":"2","effect":"Headache"},{"rate":"5","effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Oseltamivir inhibits influenza neuraminidase, an enzyme on the viral surface required for the virus to escape from infected host cells. By blocking this enzyme, the drug prevents newly formed viral particles from being released, thereby reducing viral replication and transmission. This 5-day formulation represents a shortened treatment course compared to the standard 5-day regimen.","oneSentence":"Oseltamivir is a neuraminidase inhibitor that blocks the release of influenza virus particles from infected cells, reducing viral spread.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:46:46.040Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Influenza A and B infection treatment"},{"name":"Influenza prophylaxis"}]},"trialDetails":[{"nctId":"NCT07496736","phase":"PHASE3","title":"Post-exposure Influenza Prophylaxis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Medical Centre Ljubljana","startDate":"2025-12-01","conditions":"Influenza","enrollment":200},{"nctId":"NCT07236814","phase":"PHASE3","title":"Suraxavir Marboxil And Oseltamivir for Influenza Prophylaxis Under a Hospital-based Setting","status":"RECRUITING","sponsor":"Capital Medical University","startDate":"2025-11-28","conditions":"Influenza","enrollment":384},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT04381936","phase":"PHASE3","title":"Randomised Evaluation of COVID-19 Therapy","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2020-03-19","conditions":"Severe Acute Respiratory Syndrome","enrollment":70000},{"nctId":"NCT03520049","phase":"PHASE3","title":"Proof-of-Concept: A Pilot, Randomized, Double-Blind Study of Oseltamivir Versus Placebo for Immune Thrombocytopenia","status":"UNKNOWN","sponsor":"Unity Health Toronto","startDate":"2016-11","conditions":"Immune Thrombocytopenia","enrollment":30},{"nctId":"NCT02469298","phase":"PHASE2","title":"Safety, Tolerability and Clinical Effect of Danirixin in Adults With Influenza","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-06-01","conditions":"Virus Diseases","enrollment":45},{"nctId":"NCT03754686","phase":"PHASE4","title":"Oseltamivir Versus Paracetamol for Influenza-like Illness During the Influenza Season","status":"UNKNOWN","sponsor":"Rambam Health Care Campus","startDate":"2019-02-10","conditions":"Influenza","enrollment":436},{"nctId":"NCT02282384","phase":"PHASE4","title":"An RCT of Oseltamivir in Outpatients With CPD: A Pilot Study.","status":"WITHDRAWN","sponsor":"McMaster University","startDate":"2014-10","conditions":"Pulmonary Disease, Influenza","enrollment":""},{"nctId":"NCT03365336","phase":"NA","title":"Influenza Management With Polyherbal Formulation","status":"UNKNOWN","sponsor":"Composite Interceptive Med Science","startDate":"2018-02-01","conditions":"Influenza","enrollment":100},{"nctId":"NCT02561169","phase":"PHASE4","title":"A Trial of Oseltamivir in High-Risk Patients Presenting to the Emergency Department With Influenza","status":"TERMINATED","sponsor":"McMaster University","startDate":"2015-12","conditions":"Influenza","enrollment":1},{"nctId":"NCT02989012","phase":"PHASE2","title":"Phase IIaTrials of GanMaoKangNing Granules","status":"UNKNOWN","sponsor":"Dalian Zhen-Ao Bio-Tech Co., Ltd.","startDate":"","conditions":"Epidemic Influenza","enrollment":96},{"nctId":"NCT02662426","phase":"PHASE3","title":"Lingdancao Granules in the Treatment of Seasonal Influenza","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","startDate":"2016-04","conditions":"Influenza","enrollment":318},{"nctId":"NCT02572583","phase":"PHASE1, PHASE2","title":"A Clinical Study of Treating Influenza With Liugan Shuangjie Heji","status":"UNKNOWN","sponsor":"Dongfang Hospital Beijing University of Chinese Medicine","startDate":"2014-11","conditions":"Influenza","enrollment":300},{"nctId":"NCT00921726","phase":"PHASE1","title":"Pharmacokinetic Study of Oseltamivir and Intravenous Zanamivir in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-07","conditions":"Influenza, Virus Diseases","enrollment":17}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":40,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Five-days oseltamivir","genericName":"Five-days oseltamivir","companyName":"UMC Utrecht","companyId":"umc-utrecht","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oseltamivir is a small molecule medication used to treat conditions such as influenza, pneumonia, and COVID-19. It is administered orally in a dose of 75mg.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}